These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12525639)

  • 1. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.
    Green TD; Montefiori DC; Ross TM
    J Virol; 2003 Feb; 77(3):2046-55. PubMed ID: 12525639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse strain-dependent differences in enhancement of immune responses by C3d.
    Toapanta FR; Ross TM
    Vaccine; 2004 Apr; 22(13-14):1773-81. PubMed ID: 15068861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.
    Ross TM; Xu Y; Green TD; Montefiori DC; Robinson HL
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):829-35. PubMed ID: 11429124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
    Bower JF; Yang X; Sodroski J; Ross TM
    J Virol; 2004 May; 78(9):4710-9. PubMed ID: 15078953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.
    Bower JF; Sanders KL; Ross TM
    Curr HIV Res; 2005 Apr; 3(2):191-8. PubMed ID: 15853723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
    Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
    Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
    Richmond JF; Lu S; Santoro JC; Weng J; Hu SL; Montefiori DC; Robinson HL
    J Virol; 1998 Nov; 72(11):9092-100. PubMed ID: 9765454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d.
    Koch M; Frazier J; Sodroski J; Wyatt R
    Virology; 2005 Sep; 340(2):277-84. PubMed ID: 16051303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A minimum CR2 binding domain of C3d enhances immunity following vaccination.
    Bower JF; Ross TM
    Adv Exp Med Biol; 2006; 586():249-64. PubMed ID: 16893077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression.
    Haas KM; Toapanta FR; Oliver JA; Poe JC; Weis JH; Karp DR; Bower JF; Ross TM; Tedder TF
    J Immunol; 2004 May; 172(10):5833-7. PubMed ID: 15128761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan.
    Bolmstedt A; Hinkula J; Rowcliffe E; Biller M; Wahren B; Olofsson S
    Vaccine; 2001 Nov; 20(3-4):397-405. PubMed ID: 11672902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization.
    Yang S; Wang C; Fang X; Zhai L; Dong C; Ding L; Meng J; Wang L
    Virus Res; 2010 Aug; 151(2):162-9. PubMed ID: 20451569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.